AbCellera Biologics shares more than triple in stellar debut
(Reuters) - Shares of Peter Thiel-backed AbCellera Biologics Inc, which is co-developing antibody therapies with Eli Lilly and Co for the treatment of COVID-19, surged in their debut on Friday, giving the company a market capitalization of $16.18 billion.
(Reuters) - Shares of Peter Thiel-backed AbCellera Biologics Inc, which is co-developing antibody therapies with Eli Lilly and Co for the treatment of COVID-19 , surged in their debut on Friday, giving the company a market capitalization of $16.18 billion.
AbCellera's shares opened at $61 on the Nasdaq, 204% above their upwardly revised initial public offering (IPO) price of $20 apiece on Thursday. The Canadian firm had raised $483 million in its IPO.
The biotech developer planned to sell 23 million shares priced between $17 and $18 apiece, and eventually sold 24.15 million shares.
The IPO underscores a strong demand for new biotechnology stocks, with almost half of the U.S. IPOs in 2020 coming from the healthcare sector, according to data from IPOScoop.
The U.S. has purchased 950,000 doses of Bamlanivimab, a COVID-19 antibody therapy co-developed by Lilly and AbCellera, which has been authorized for emergency use by the U.S. Food and Drug Administration. A supply agreement has also been signed with the Canadian government for 26,000 doses.
AbCellera has also got government support, receiving $30.6 million from the U.S. Defense Advanced Research Platform's pandemic prevention program and C$175.6 million ($137.57 million) from the Canadian government's Strategic Innovation Fund.
Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Market were the lead underwriters for the offering.
($1 = 1.2764 Canadian dollars)
(Reporting by Sohini Podder in Bengaluru; Editing by Vinay Dwivedi)
This story has not been edited by Firstpost staff and is generated by auto-feed.
Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.
By Uday Sampath Kumar (Reuters) - Target Corp reported a 17.2% rise in comparable sales for the holiday season on Wednesday as its online sales more than doubled, thanks to faster deliveries and higher demand for home goods, electronics and beauty products.
By Medha Singh and Devik Jain (Reuters) - The S&P 500 and the Nasdaq rose in choppy trading on Wednesday as Intel shares jumped thanks to a change in management while broader sentiment was muted after a recent run to record highs. Intel said it would replace Chief Executive Officer Bob Swan with VMware Inc CEO Pat Gelsinger next month
By Danny Ramos LA PAZ (Reuters) - The Bolivian government said on Wednesday it had signed a contract with India's Serum Institute for the supply of 5 million doses of AstraZeneca's COVID-19 vaccine. President Luis Arce said that combined with a recent deal to buy 5.2 million Sputnik V vaccine doses from Russia, Bolivia now expected to be able to inoculate all of its vaccinable population. Both vaccines require two doses to be given, meaning they would be used to inoculate a total of 5.1 million people from Bolivia's 11.51 million-strong population.